Annual Cash & Cash Equivalents
$14.93 M
-$8.46 M-36.19%
September 30, 2024
Summary
- As of February 12, 2025, OTLK annual cash & cash equivalents is $14.93 million, with the most recent change of -$8.46 million (-36.19%) on September 30, 2024.
- During the last 3 years, OTLK annual cash & cash equivalents has risen by +$450.20 thousand (+3.11%).
- OTLK annual cash & cash equivalents is now -36.19% below its all-time high of $23.39 million, reached on September 30, 2023.
Performance
OTLK Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$14.93 M
-$17.10 M-53.39%
September 30, 2024
Summary
- As of February 12, 2025, OTLK quarterly cash and cash equivalents is $14.93 million, with the most recent change of -$17.10 million (-53.39%) on September 30, 2024.
- Over the past year, OTLK quarterly cash and cash equivalents has increased by +$4.57 million (+44.14%).
- OTLK quarterly cash and cash equivalents is now -78.72% below its all-time high of $70.15 million, reached on December 31, 2021.
Performance
OTLK Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
OTLK Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -36.2% | +44.1% |
| 3 y3 years | +3.1% | +3.1% |
| 5 y5 years | +86.2% | +220.8% |
OTLK Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -36.2% | +3.1% | -78.7% | +44.1% |
| 5 y | 5-year | -36.2% | +86.2% | -78.7% | +1019.3% |
| alltime | all time | -36.2% | +769.2% | -78.7% | >+9999.0% |
Outlook Therapeutics Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | $14.93 M(-36.2%) | $14.93 M(-53.4%) |
| Jun 2024 | - | $32.02 M(-32.2%) |
| Mar 2024 | - | $47.23 M(+356.0%) |
| Dec 2023 | - | $10.36 M(-55.7%) |
| Sep 2023 | $23.39 M(+34.5%) | $23.39 M(-30.6%) |
| Jun 2023 | - | $33.71 M(-22.7%) |
| Mar 2023 | - | $43.63 M(-16.6%) |
| Dec 2022 | - | $52.34 M(+200.9%) |
| Sep 2022 | $17.40 M(+20.2%) | $17.40 M(-33.1%) |
| Jun 2022 | - | $26.02 M(-55.5%) |
| Mar 2022 | - | $58.42 M(-16.7%) |
| Dec 2021 | - | $70.15 M(+384.6%) |
| Sep 2021 | $14.48 M(+15.5%) | $14.48 M(-26.5%) |
| Jun 2021 | - | $19.69 M(-47.0%) |
| Mar 2021 | - | $37.17 M(+567.5%) |
| Dec 2020 | - | $5.57 M(-55.6%) |
| Sep 2020 | $12.54 M | $12.54 M(-47.7%) |
| Jun 2020 | - | $23.95 M(+414.8%) |
| Mar 2020 | - | $4.65 M(+248.9%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2019 | - | $1.33 M(-83.4%) |
| Sep 2019 | $8.02 M(+366.7%) | $8.02 M(-42.9%) |
| Jun 2019 | - | $14.03 M(+8920.5%) |
| Mar 2019 | - | $155.50 K(-31.7%) |
| Dec 2018 | - | $227.70 K(-86.7%) |
| Sep 2018 | $1.72 M(-46.1%) | $1.72 M(-85.4%) |
| Jun 2018 | - | $11.80 M(+98.7%) |
| Mar 2018 | - | $5.94 M(-57.1%) |
| Dec 2017 | - | $13.84 M(+334.4%) |
| Sep 2017 | $3.19 M(+35.4%) | $3.19 M(+2177.0%) |
| Jun 2017 | - | $139.90 K(+72.7%) |
| Mar 2017 | - | $81.00 K(-96.1%) |
| Dec 2016 | - | $2.08 M(-11.6%) |
| Sep 2016 | $2.35 M(-74.1%) | $2.35 M(-82.6%) |
| Jun 2016 | - | $13.56 M(+376.9%) |
| Mar 2016 | - | $2.84 M(-73.7%) |
| Dec 2015 | - | $10.81 M(+19.1%) |
| Sep 2015 | $9.07 M(0.0%) | $9.07 M |
| Sep 2014 | $9.07 M | - |
FAQ
- What is Outlook Therapeutics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Outlook Therapeutics?
- What is Outlook Therapeutics annual cash & cash equivalents year-on-year change?
- What is Outlook Therapeutics quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Outlook Therapeutics?
- What is Outlook Therapeutics quarterly cash and cash equivalents year-on-year change?
What is Outlook Therapeutics annual cash & cash equivalents?
The current annual cash & cash equivalents of OTLK is $14.93 M
What is the all time high annual cash & cash equivalents for Outlook Therapeutics?
Outlook Therapeutics all-time high annual cash & cash equivalents is $23.39 M
What is Outlook Therapeutics annual cash & cash equivalents year-on-year change?
Over the past year, OTLK annual cash & cash equivalents has changed by -$8.46 M (-36.19%)
What is Outlook Therapeutics quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of OTLK is $14.93 M
What is the all time high quarterly cash and cash equivalents for Outlook Therapeutics?
Outlook Therapeutics all-time high quarterly cash and cash equivalents is $70.15 M
What is Outlook Therapeutics quarterly cash and cash equivalents year-on-year change?
Over the past year, OTLK quarterly cash and cash equivalents has changed by +$4.57 M (+44.14%)